Sorafenib for the treatment of unresectable hepatocellular carcinoma

Por Furuse, Junji
Publicado em 2008

Targeted Therapy for Biliary Tract Cancer

Por Furuse, Junji, Okusaka, Takuji
Publicado em 2011

A pathological complete response after combined chemotherapy of gemcitabine and S-1 in advanced biliary tract cancer with para-aortic lymph nodes metastasis: a case report

Por Watanabe, Takeshi, Furuse, Junji, Okano, Naohiro, Suzuki, Yutaka, Kamma, Hiroshi, Sugiyama, Masanori
Publicado no Surg Case Rep (2017)

Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study

Por Fukutomi, Akira, Furuse, Junji, Okusaka, Takuji, Miyazaki, Masaru, Taketsuna, Masanori, Koshiji, Minori, Nimura, Yuji
Publicado em 2012

Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)

Por Mizusawa, Junki, Morizane, Chigusa, Okusaka, Takuji, Katayama, Hiroshi, Ishii, Hiroshi, Fukuda, Haruhiko, Furuse, Junji
Publicado no Jpn J Clin Oncol (2016)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

Por Okusaka, Takuji, Ikeda, Masafumi, Fukutomi, Akira, Ioka, Tatsuya, Furuse, Junji, Ohkawa, Shinichi, Isayama, Hiroyuki, Boku, Narikazu
Publicado no Cancer Sci (2014)

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Por Okusaka, Takuji, Ikeda, Masafumi, Fukutomi, Akira, Ioka, Tatsuya, Furuse, Junji, Ohkawa, Shinichi, Isayama, Hiroyuki, Boku, Narikazu
Publicado no Cancer Sci (2015)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma

Por Ikeda, Masafumi, Ohkawa, Shinichi, Okusaka, Takuji, Mitsunaga, Shuichi, Kobayashi, Satoshi, Morizane, Chigusa, Suzuki, Ikue, Yamamoto, Shunsuke, Furuse, Junji
Publicado no Cancer Sci (2014)

KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers

Por Yokoyama, Masaaki, Ohnishi, Hiroaki, Ohtsuka, Kouki, Matsushima, Satsuki, Ohkura, Yasuo, Furuse, Junji, Watanabe, Takashi, Mori, Toshiyuki, Sugiyama, Masanori
Publicado no Jpn Clin Med (2016)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial

Por Ito, Tetsuhide, Okusaka, Takuji, Ikeda, Masafumi, Igarashi, Hisato, Morizane, Chigusa, Nakachi, Kohei, Tajima, Takeshi, Kasuga, Akio, Fujita, Yoshie, Furuse, Junji
Publicado em 2012

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

Por Suzuki, Eiichiro, Ikeda, Masafumi, Okusaka, Takuji, Nakamori, Shoji, Ohkawa, Shinichi, Nagakawa, Tatsuya, Boku, Narikazu, Yanagimoto, Hiroaki, Sato, Tosiya, Furuse, Junji
Publicado em 2013

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Por Sunakawa, Yu, Furuse, Junji, Okusaka, Takuji, Ikeda, Masafumi, Nagashima, Fumio, Ueno, Hideki, Mitsunaga, Shuichi, Hashizume, Kensei, Ito, Yuichiro, Sasaki, Yasutsuna
Publicado em 2013

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

Por Sunakawa, Yu, Furuse, Junji, Okusaka, Takuji, Ikeda, Masafumi, Nagashima, Fumio, Ueno, Hideki, Mitsunaga, Shuichi, Hashizume, Kensei, Ito, Yuichiro, Sasaki, Yasutsuna
Publicado em 2013

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors

Por Okusaka, Takuji, Aramaki, Takeshi, Inaba, Yoshitaka, Nakamura, Shinichiro, Morimoto, Manabu, Moriguchi, Michihisa, Sato, Takashi, Ikawa, Yuta, Ikeda, Masafumi, Furuse, Junji
Publicado no Cancer Sci (2015)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surv...

Por Kaneko, Shuichi, Ikeda, Kenji, Matsuzaki, Yasushi, Furuse, Junji, Minami, Hironobu, Okayama, Yutaka, Sunaya, Toshiyuki, Ito, Yuichiro, Inuyama, Lyo, Okita, Kiwamu
Publicado no J Gastroenterol (2016)

A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients

Por MATSUNAGA, MOTOTSUGU, KANETA, TOSHIKADO, MIWA, KEISUKE, ICHIKAWA, WATARU, FUJITA, KEN-ICHI, NAGASHIMA, FUMIO, FURUSE, JUNJI, KAGE, MASAYOSHI, AKAGI, YOSHITO, SASAKI, YASUTSUNA
Publicado no Oncol Lett (2016)

High-Resolution Computed Tomography Findings for Patients With Drug-Induced Pulmonary Toxicity, With Special Reference to Hypersensitivity Pneumonitis-Like Patterns in Gemcitabine-...

Por Tamura, Masaki, Saraya, Takeshi, Fujiwara, Masachika, Hiraoka, Sayuki, Yokoyama, Takuma, Yano, Kinuko, Ishii, Haruyuki, Furuse, Junji, Goya, Tomoyuki, Takizawa, Hajime, Goto, Hajime
Publicado em 2013

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Por Kudo, Masatoshi, Ikeda, Masafumi, Takayama, Tadatoshi, Numata, Kazushi, Izumi, Namiki, Furuse, Junji, Okusaka, Takuji, Kadoya, Masumi, Yamashita, Satoshi, Ito, Yuichiro, Kokudo, Norihiro
Publicado no J Gastroenterol (2016)

Germline mutations in Japanese familial pancreatic cancer patients

Por Takai, Erina, Yachida, Shinichi, Shimizu, Kyoko, Furuse, Junji, Kubo, Emi, Ohmoto, Akihiro, Suzuki, Masami, Hruban, Ralph H., Okusaka, Takuji, Morizane, Chigusa, Furukawa, Toru
Publicado no Oncotarget (2016)

Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment

Por Suyama, Koichi, Ikeda, Masafumi, Suzuki, Eiichiro, Kojima, Motohiro, Mitsunaga, Shuichi, Shimizu, Satoshi, Ohno, Izumi, Takahashi, Hideaki, Okuyama, Hiroyuki, Kuwahara, Akiko, Okusaka, Takuji, Furuse, Junji
Publicado em 2013